Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 42.72
(0.73%)
INR 42.72
(0.73%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 7.09 Million INR | 26.55% |
| 2022 | 5.6 Million INR | -19.76% |
| 2021 | 6.98 Million INR | -43.74% |
| 2020 | 12.41 Million INR | 2.83% |
| 2019 | 12.07 Million INR | 150.3% |
| 2018 | 4.82 Million INR | 2.46% |
| 2017 | 4.7 Million INR | -73.77% |
| 2016 | 17.94 Million INR | 129.25% |
| 2015 | 7.82 Million INR | 33.29% |
| 2014 | 5.87 Million INR | 13.65% |
| 2013 | 5.16 Million INR | -4.75% |
| 2012 | 5.42 Million INR | 260.33% |
| 2011 | 1.5 Million INR | -84.82% |
| 2010 | 9.91 Million INR | 82.07% |
| 2009 | 5.44 Million INR | 306.99% |
| 2008 | -2.63 Million INR | 60.57% |
| 2007 | -6.67 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.69 Million INR | -31.95% |
| 2023 Q1 | 2.44 Million INR | 17.07% |
| 2023 Q3 | 933 Thousand INR | -24.08% |
| 2023 Q4 | 2.48 Million INR | 166.67% |
| 2023 FY | 7.09 Million INR | 26.55% |
| 2023 Q2 | 1.22 Million INR | -49.67% |
| 2022 Q2 | 455 Thousand INR | -77.93% |
| 2022 FY | 5.6 Million INR | -19.76% |
| 2022 Q4 | 2.08 Million INR | 108.39% |
| 2022 Q3 | 1 Million INR | 120.0% |
| 2022 Q1 | 2.06 Million INR | 820.98% |
| 2021 Q1 | 1.73 Million INR | 141.91% |
| 2021 FY | 6.98 Million INR | -43.74% |
| 2021 Q3 | 3.4 Million INR | 60.11% |
| 2021 Q2 | 2.12 Million INR | 22.25% |
| 2021 Q4 | -286 Thousand INR | -108.4% |
| 2020 Q4 | -4.14 Million INR | -180.96% |
| 2020 Q2 | 9.27 Million INR | 328.02% |
| 2020 Q3 | 5.12 Million INR | -44.72% |
| 2020 FY | 12.41 Million INR | 2.83% |
| 2020 Q1 | 2.16 Million INR | 46.75% |
| 2019 Q4 | 1.47 Million INR | -35.66% |
| 2019 FY | 12.07 Million INR | 150.3% |
| 2019 Q1 | 389 Thousand INR | 91.63% |
| 2019 Q2 | 7.91 Million INR | 1934.19% |
| 2019 Q3 | 2.29 Million INR | -71.01% |
| 2018 Q4 | 203 Thousand INR | -93.07% |
| 2018 FY | 4.82 Million INR | 2.46% |
| 2018 Q1 | 641 Thousand INR | -17.18% |
| 2018 Q2 | 1.04 Million INR | 63.49% |
| 2018 Q3 | 2.93 Million INR | 179.68% |
| 2017 Q3 | 2.23 Million INR | 209.99% |
| 2017 Q1 | 976 Thousand INR | -90.27% |
| 2017 Q2 | 721 Thousand INR | -26.13% |
| 2017 FY | 4.7 Million INR | -73.77% |
| 2017 Q4 | 774 Thousand INR | -65.37% |
| 2016 Q3 | 4.92 Million INR | 79.68% |
| 2016 Q2 | 2.73 Million INR | 982.61% |
| 2016 Q1 | 253 Thousand INR | -95.13% |
| 2016 Q4 | 10.03 Million INR | 103.8% |
| 2016 FY | 17.94 Million INR | 129.25% |
| 2015 FY | 7.82 Million INR | 33.29% |
| 2015 Q3 | 1.21 Million INR | 37.33% |
| 2015 Q1 | 531 Thousand INR | -82.63% |
| 2015 Q2 | 884 Thousand INR | 66.48% |
| 2015 Q4 | 5.19 Million INR | 328.17% |
| 2014 Q2 | 1.5 Million INR | 197.62% |
| 2014 Q4 | 3.05 Million INR | 1348.68% |
| 2014 FY | 5.87 Million INR | 13.65% |
| 2014 Q3 | 211 Thousand INR | -85.93% |
| 2014 Q1 | 504 Thousand INR | 49.39% |
| 2013 Q3 | 4.08 Million INR | 1344.88% |
| 2013 Q1 | 457 Thousand INR | -89.17% |
| 2013 FY | 5.16 Million INR | -4.75% |
| 2013 Q2 | 283 Thousand INR | -38.07% |
| 2013 Q4 | 337.38 Thousand INR | -91.75% |
| 2012 Q1 | 513 Thousand INR | 322.9% |
| 2012 Q4 | 4.21 Million INR | 1098.32% |
| 2012 FY | 5.42 Million INR | 260.33% |
| 2012 Q3 | 352 Thousand INR | 2.92% |
| 2012 Q2 | 342 Thousand INR | -33.33% |
| 2011 FY | 1.5 Million INR | -84.82% |
| 2011 Q4 | 121.3 Thousand INR | -65.04% |
| 2011 Q3 | 347 Thousand INR | 0.0% |
| 2010 FY | 9.91 Million INR | 82.07% |
| 2009 FY | 5.44 Million INR | 306.99% |
| 2008 FY | -2.63 Million INR | 60.57% |
| 2008 Q4 | -3.43 Million INR | 0.0% |
| 2007 FY | -6.67 Million INR | 0.0% |
| 2007 Q4 | -4.93 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 99.885% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.978% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 99.849% |
| Granules India Limited | 4.05 Billion INR | 99.825% |
| Indoco Remedies Limited | 984.6 Million INR | 99.28% |
| Achyut Healthcare Limited | 5.73 Million INR | -23.726% |
| Ajanta Pharma Limited | 8.16 Billion INR | 99.913% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.961% |
| Alpa Laboratories Limited | 167.76 Million INR | 95.773% |
| Brooks Laboratories Limited | -195.91 Million INR | 103.62% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 99.561% |
| Bajaj HealthCare Limited | -837.93 Million INR | 100.846% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 99.06% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.987% |
| Eris Lifesciences Limited | 3.91 Billion INR | 99.819% |
| FDC Limited | 3.05 Billion INR | 99.768% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.047% |
| Gufic Biosciences Limited | 861.35 Million INR | 99.177% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 99.832% |
| Ipca Laboratories Limited | 5.47 Billion INR | 99.87% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 96.843% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 103.595% |
| Lasa Supergenerics Limited | -217.3 Million INR | 103.264% |
| Laurus Labs Limited | 1.6 Billion INR | 99.558% |
| Lupin Limited | 19.14 Billion INR | 99.963% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.963% |
| Medicamen Biotech Limited | 109.31 Million INR | 93.512% |
| Medico Remedies Limited | 82.9 Million INR | 91.446% |
| Megasoft Limited | -127.46 Million INR | 105.564% |
| NATCO Pharma Limited | 13.88 Billion INR | 99.949% |
| Piramal Pharma Limited | 178.2 Million INR | 96.02% |
| RPG Life Sciences Limited | 876.6 Million INR | 99.191% |
| Sigachi Industries Limited | 571.8 Million INR | 98.76% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.993% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 99.764% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 97.198% |
| Unichem Laboratories Limited | -704.74 Million INR | 101.006% |
| Wanbury Limited | 559.56 Million INR | 98.733% |
| Windlas Biotech Limited | 581.87 Million INR | 98.781% |
| ZIM Laboratories Limited | 172.46 Million INR | 95.888% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.982% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 100.183% |
| Divi's Laboratories Limited | 16 Billion INR | 99.956% |
| Hester Biosciences Limited | 188.89 Million INR | 96.245% |
| Procter & Gamble Health Limited | 2 Billion INR | 99.647% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 98.423% |
| Bal Pharma Limited | 73.92 Million INR | 90.406% |
| Strides Pharma Science Limited | -706.14 Million INR | 101.004% |
| Venus Remedies Limited | 284.9 Million INR | 97.511% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 99.673% |
| Nectar Lifesciences Limited | 49.95 Million INR | 85.802% |
| Shilpa Medicare Limited | 318.74 Million INR | 97.775% |
| Aarti Drugs Limited | 1.71 Billion INR | 99.586% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 99.472% |
| Suven Life Sciences Limited | -1.05 Billion INR | 100.675% |
| Ind-Swift Limited | 142.31 Million INR | 95.017% |
| Valiant Laboratories Limited | 3.19 Million INR | -121.902% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 99.872% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 100.125% |
| Themis Medicare Limited | 435.23 Million INR | 98.371% |
| Hikal Limited | 696.02 Million INR | 98.981% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.957% |
| Sequent Scientific Limited | -358.69 Million INR | 101.977% |
| Novartis India Limited | 851.9 Million INR | 99.168% |
| Wockhardt Limited | -4.63 Billion INR | 100.153% |
| Jubilant Pharmova Limited | 771 Million INR | 99.08% |
| Neuland Laboratories Limited | 3 Billion INR | 99.764% |
| Morepen Laboratories Limited | 961.59 Million INR | 99.262% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 95.143% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 107.818% |